{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:59:25Z","timestamp":1774418365953,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04091-w","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:23:24Z","timestamp":1761056604000},"page":"1223-1233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug allergy history predicts early progression-free survival benefit from PD-(L)1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-5270","authenticated-orcid":false,"given":"Wenhao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8978-892X","authenticated-orcid":false,"given":"Min","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8230-5892","authenticated-orcid":false,"given":"Youling","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3390-9697","authenticated-orcid":false,"given":"Meijuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-7538","authenticated-orcid":false,"given":"Jianxin","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1671-1408","authenticated-orcid":false,"given":"You","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"4091_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"4091_CR2","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/B978-0-323-47674-4.00069-4","volume-title":"Abeloff's clinical oncology","author":"LH Araujo","year":"2020","unstructured":"Araujo LH, Horn L, Merritt RE, Shilo K, Xu-Welliver M, Carbone DP. Cancer of the lung: non\u2013small cell lung cancer and small cell lung cancer. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, editors. Abeloff\u2019s clinical oncology. Amsterdam: Elsevier; 2020. p. 1108\u201358."},{"issue":"10","key":"4091_CR3","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1200\/JCO-24-02785","volume":"43","author":"DH Owen","year":"2025","unstructured":"Owen DH, Ismaila N, Ahluwalia A, Feldman J, Gadgeel S, Mullane M, et al. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline, Version 2024.3. J Clin Oncol. 2025;43(10):e2-16.","journal-title":"J Clin Oncol"},{"key":"4091_CR4","unstructured":"C. for D.E. and Research, FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC, FDA (2019). https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc (accessed July 2, 2025)."},{"key":"4091_CR5","unstructured":"FDA Approves Perioperative Pembrolizumab Plus Chemotherapy in Early NSCLC, (n.d.). https:\/\/www.targetedonc.com\/view\/fda-approves-perioperative-pembrolizumab-plus-chemotherapy-in-early-nsclc?utm_source=chatgpt.com (accessed July 2, 2025)."},{"issue":"11","key":"4091_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1200\/JCO.23.02744","volume":"42","author":"IA Jaiyesimi","year":"2024","unstructured":"Jaiyesimi IA, Leighl NB, Ismaila N, Alluri K, Florez N, Gadgeel S, et al. Therapy for stage IV non\u2013small cell lung cancer with driver alterations: ASCO living guideline, version 2023.3. J Clin Oncol. 2024;42(11):e1-22.","journal-title":"J Clin Oncol"},{"key":"4091_CR7","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1001\/jama.2019.3241","volume":"321","author":"G Singal","year":"2019","unstructured":"Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA. 2019;321:1391\u20139. https:\/\/doi.org\/10.1001\/jama.2019.3241.","journal-title":"JAMA"},{"key":"4091_CR8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"4091_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00222","volume":"11","author":"NB Alsaleh","year":"2020","unstructured":"Alsaleh NB, Brown JM. Engineered nanomaterials and type I allergic hypersensitivity reactions. Front Immunol. 2020;11:222. https:\/\/doi.org\/10.3389\/fimmu.2020.00222.","journal-title":"Front Immunol"},{"key":"4091_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri1589","volume":"5","author":"CM Hawrylowicz","year":"2005","unstructured":"Hawrylowicz CM, O\u2019Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol. 2005;5:271\u201383. https:\/\/doi.org\/10.1038\/nri1589.","journal-title":"Nat Rev Immunol"},{"key":"4091_CR11","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.immuni.2020.10.002","volume":"53","author":"JA Turner","year":"2020","unstructured":"Turner JA, Stephen-Victor E, Wang S, Rivas MN, Abdel-Gadir A, Harb H, et al. Regulatory T cell-derived TGF-\u03b21 controls multiple checkpoints governing allergy and autoimmunity. Immunity. 2020;53:1202-1214.e6. https:\/\/doi.org\/10.1016\/j.immuni.2020.10.002.","journal-title":"Immunity"},{"key":"4091_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2147\/JAA.S472632","volume":"17","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhang R, Li J, Wang H, Wang M, Ren Q, et al. Association between gut and nasal microbiota and allergic rhinitis: a systematic review. J Asthma Allergy. 2024;17:633\u201351. https:\/\/doi.org\/10.2147\/JAA.S472632.","journal-title":"J Asthma Allergy"},{"key":"4091_CR13","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1038\/s41467-023-40336-4","volume":"14","author":"C Hoskinson","year":"2023","unstructured":"Hoskinson C, Dai DLY, Del Bel KL, Becker AB, Moraes TJ, Mandhane PJ, et al. Delayed gut microbiota maturation in the first year of life is a hallmark of pediatric allergic disease. Nat Commun. 2023;14:4785. https:\/\/doi.org\/10.1038\/s41467-023-40336-4.","journal-title":"Nat Commun"},{"key":"4091_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/ACI.0b013e3283507927","volume":"12","author":"AA Litonjua","year":"2012","unstructured":"Litonjua AA. Vitamin D deficiency as a risk factor for childhood allergic disease and asthma. Curr Opin Allergy Clin Immunol. 2012;12:179\u201385. https:\/\/doi.org\/10.1097\/ACI.0b013e3283507927.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"4091_CR15","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molmed.2022.06.003","volume":"28","author":"A Lorentz","year":"2022","unstructured":"Lorentz A, Bilotta S, Civelek M. Molecular links between allergy and cancer. Trends Mol Med. 2022;28:1070\u201381. https:\/\/doi.org\/10.1016\/j.molmed.2022.06.003.","journal-title":"Trends Mol Med"},{"key":"4091_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s12016-025-09065-y","volume":"68","author":"J Wen","year":"2025","unstructured":"Wen J, Lan Z, He L, Long H. Aberrant activation of mast cells: molecular mechanisms and targets for intervention. Clin Rev Allergy Immunol. 2025;68:60. https:\/\/doi.org\/10.1007\/s12016-025-09065-y.","journal-title":"Clin Rev Allergy Immunol"},{"key":"4091_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.neo.2017.02.014","volume":"19","author":"DJ Son","year":"2017","unstructured":"Son DJ, Jung YY, Park MH, Lee HL, Song MJ, Yoo H-S, et al. Activated natural killer cells mediate the suppressive effect of interleukin-4 on tumor development via STAT6 activation in an atopic condition melanoma model. Neoplasia. 2017;19:537\u201348. https:\/\/doi.org\/10.1016\/j.neo.2017.02.014.","journal-title":"Neoplasia"},{"issue":"197","key":"4091_CR18","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.4049\/jimmunol.1601026","volume":"1950","author":"EA Nigro","year":"2016","unstructured":"Nigro EA, Brini AT, Yenagi VA, Ferreira LM, Achatz-Straussberger G, Ambrosi A, et al. Cutting edge: IgE plays an active role in tumor immunosurveillance in mice. J Immunol Baltim Md. 2016;1950(197):2583\u20138. https:\/\/doi.org\/10.4049\/jimmunol.1601026.","journal-title":"J Immunol Baltim Md"},{"key":"4091_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.418","volume":"7","author":"M Akimoto","year":"2016","unstructured":"Akimoto M, Hayashi J-I, Nakae S, Saito H, Takenaga K. Interleukin-33 enhances programmed oncosis of ST2L-positive low-metastatic cells in the tumour microenvironment of lung cancer. Cell Death Dis. 2016;7:e2057. https:\/\/doi.org\/10.1038\/cddis.2015.418.","journal-title":"Cell Death Dis"},{"key":"4091_CR20","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3390\/biom11081232","volume":"11","author":"PL Nguyen","year":"2021","unstructured":"Nguyen PL, Cho J. Pathophysiological roles of histamine receptors in cancer progression: implications and perspectives as potential molecular targets. Biomolecules. 2021;11:1232. https:\/\/doi.org\/10.3390\/biom11081232.","journal-title":"Biomolecules"},{"key":"4091_CR21","doi-asserted-by":"publisher","first-page":"e00778","DOI":"10.1002\/prp2.778","volume":"9","author":"MD Sarasola","year":"2021","unstructured":"Sarasola MD, Taquez Delgado MA, Nicoud MB, Medina VA. Histamine in cancer immunology and immunotherapy. Current status and new perspectives. Pharmacol Res Perspect. 2021;9:e00778. https:\/\/doi.org\/10.1002\/prp2.778.","journal-title":"Pharmacol Res Perspect"},{"key":"4091_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","volume":"40","author":"H Li","year":"2022","unstructured":"Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40:36-52.e9. https:\/\/doi.org\/10.1016\/j.ccell.2021.11.002.","journal-title":"Cancer Cell"},{"key":"4091_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.670391","volume":"12","author":"M Wang","year":"2021","unstructured":"Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, et al. The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors. Front Immunol. 2021;12:670391. https:\/\/doi.org\/10.3389\/fimmu.2021.670391.","journal-title":"Front Immunol"},{"key":"4091_CR24","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3390\/biom15040491","volume":"15","author":"F Omero","year":"2025","unstructured":"Omero F, Speranza D, Murdaca G, Cavaleri M, Marafioti M, Cianci V, et al. The role of eosinophils, eosinophil-related cytokines and AI in predicting immunotherapy efficacy in NSCLC. Biomolecules. 2025;15:491. https:\/\/doi.org\/10.3390\/biom15040491.","journal-title":"Biomolecules"},{"issue":"45","key":"4091_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"1990","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Engl. 2009;1990(45):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"4091_CR26","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112:90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas Dermosifiliogr"},{"key":"4091_CR27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","volume":"22","author":"JA Thompson","year":"2024","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Zaid MA, Achufusi A, Armand P, et al. NCCN guidelines\u00ae insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Cancer Netw JNCCN. 2024;22:582\u201392. https:\/\/doi.org\/10.6004\/jnccn.2024.0057.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"4091_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJM200101043440106","volume":"344","author":"AB Kay","year":"2001","unstructured":"Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001;344:30\u20137. https:\/\/doi.org\/10.1056\/NEJM200101043440106.","journal-title":"N Engl J Med"},{"key":"4091_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.celrep.2015.02.015","volume":"10","author":"B Platzer","year":"2015","unstructured":"Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, et al. IgE\/Fc\u03b5ri-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep. 2015;10:1487\u201395. https:\/\/doi.org\/10.1016\/j.celrep.2015.02.015.","journal-title":"Cell Rep"},{"key":"4091_CR30","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.molmed.2020.03.002","volume":"26","author":"G Pellizzari","year":"2020","unstructured":"Pellizzari G, Bax HJ, Josephs DH, Gotovina J, Jensen-Jarolim E, Spicer JF, et al. Harnessing therapeutic IgE antibodies to re-educate macrophages against cancer. Trends Mol Med. 2020;26:615\u201326. https:\/\/doi.org\/10.1016\/j.molmed.2020.03.002.","journal-title":"Trends Mol Med"},{"key":"4091_CR31","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","volume":"49","author":"CS Garris","year":"2018","unstructured":"Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-\u03b3 and IL-12. Immunity. 2018;49:1148-1161.e7. https:\/\/doi.org\/10.1016\/j.immuni.2018.09.024.","journal-title":"Immunity"},{"key":"4091_CR32","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/0008-5472.CAN-18-3208","volume":"79","author":"H Xiong","year":"2019","unstructured":"Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y, et al. Anti\u2013PD-l1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 2019;79:1493\u2013506. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3208.","journal-title":"Cancer Res"},{"key":"4091_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004605","volume":"10","author":"D Noyes","year":"2022","unstructured":"Noyes D, Bag A, Oseni S, Semidey-Hurtado J, Cen L, Sarnaik AA, et al. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells. J Immunother Cancer. 2022;10:e004605. https:\/\/doi.org\/10.1136\/jitc-2022-004605.","journal-title":"J Immunother Cancer"},{"key":"4091_CR34","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci. 2019;116:9999\u201310008. https:\/\/doi.org\/10.1073\/pnas.1822001116.","journal-title":"Proc Natl Acad Sci"},{"key":"4091_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1084\/jem.20131142","volume":"211","author":"KS Smigiel","year":"2014","unstructured":"Smigiel KS, Richards E, Srivastava S, Thomas KR, Dudda JC, Klonowski KD, et al. Ccr7 provides localized access to IL-2 and defines homeostatically distinct regulatory T cell subsets. J Exp Med. 2014;211:121\u201336. https:\/\/doi.org\/10.1084\/jem.20131142.","journal-title":"J Exp Med"},{"key":"4091_CR36","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.3390\/biomedicines12102381","volume":"12","author":"C Tomassetti","year":"2024","unstructured":"Tomassetti C, Insinga G, Gimigliano F, Morrione A, Giordano A, Giurisato E. Insights into CSF-1R expression in the tumor microenvironment. Biomedicines. 2024;12:2381. https:\/\/doi.org\/10.3390\/biomedicines12102381.","journal-title":"Biomedicines"},{"key":"4091_CR37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3389\/fimmu.2018.01930","volume":"9","author":"P Ruytinx","year":"2018","unstructured":"Ruytinx P, Proost P, Van Damme J, Struyf S. Chemokine-induced macrophage polarization in inflammatory conditions. Front Immunol. 2018;9:1930. https:\/\/doi.org\/10.3389\/fimmu.2018.01930.","journal-title":"Front Immunol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04091-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04091-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04091-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T05:06:07Z","timestamp":1774415167000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04091-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4091"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04091-w","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of West China Hospital, Sichuan University (approval number: 2024320). Given the retrospective cohort design, the Ethics Committee waived the requirement for informed patient consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and Informed consent"}}]}}